3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
3
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Brain Neoplasms
1
Interventions
Temozolomide
2
Filgrastim
2
Everolimus
2
trifluridine tipiracil drug combination
1
sargramostim
1
poly ICLC
1
pegfilgrastim
1
pasireotide
1
gadobutrol
1
gadobenic acid
1
dactolisib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Yoga
1
Vaccines
1
Topotecan
1
Surgical Procedures, Operative
1
Radiotherapy
1
O(6)-benzylguanine
1
Methylphenidate
1
Magnetic Resonance Spectroscopy
1
Genistein
1
Gadolinium DTPA
1
Decitabine
1
Cyclophosphamide
1
Congresses as Topic
1
Carmustine
1
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neuroectodermal Tumors, Primitive
×
Genistein
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts